newsfilter
← Latest News
GlobeNewswire·

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic,